Medication info
Exiglumem Sustained Release Tablet 10/500 mg

Exiglumem Sustained Release Tablet 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin›10mg / 1 tablet
Manufacturer / importer
Jongkeundang Co., Ltd.
Appearance
Pink, convex on both sides, oblong sustained-release film-coated tablet
Packaging
10 tablets/box [10 tablets/PTP x 1], 30 tablets/bottle, 30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202107476 · Approved 2021.11.15 · Insurance code 643309180

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other antihyperglycemic agents. Because changes may result in altered glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other condition that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted by the kidneys, and renal function is more likely to decline in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Ingredients

Manufacturer
Jongkeundang Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication helps to control blood sugar levels in adults with type 2 diabetes when used in conjunction with dapagliflozin and metformin. It can effectively manage blood sugar when used with dietary and exercise therapy. It is particularly suitable for type 2 diabetes patients whose blood sugar is not adequately controlled and who have cardiovascular disease or risk factors. This medication may aid not only in blood sugar control but also in managing the risk of cardiovascular events, so precautions should be checked before use. Overall, it is used for controlling blood sugar levels and managing cardiovascular health.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other antihyperglycemic agents. Because changes may result in altered glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other condition that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted by the kidneys, and renal function is more likely to decline in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Precautions

This medication may very rarely cause a serious condition known as lactic acidosis. Lactic acidosis occurs when there is an excessive buildup of lactic acid in the body, and this condition can be fatal, so caution is needed. If taken with other diabetes medications, hypoglycemia may occur, so blood sugar levels should be closely monitored. This medication should not be used in patients with severely compromised kidney function, dehydration, severe infections, or acute heart issues. Pregnant or breastfeeding women should not take this medication. Furthermore, patients with specific genetic issues like lactose intolerance should also refrain from using this medication. Elderly patients or those with diminished kidney function must check their fluid status and renal function prior to taking this medication and monitor regularly during treatment. This medication may increase the risk of infections such as genital infections or urinary tract infections, so if symptoms of infection develop, consult a doctor promptly. During treatment, be vigilant for signs of dehydration or low blood pressure; if these symptoms occur, notify medical personnel. This medication may lower vitamin B12 levels, so monitoring blood vitamin B12 concentrations is advised during long-term treatment. Excessive alcohol consumption may enhance the risk of side effects, so it should be avoided. If planning surgery or radiocontrast examinations, this medication should be discontinued for a period, and kidney function testing is required before resuming. Immediate consultation with medical staff is required if severe abdominal pain, difficulty breathing, or profound lethargy occurs while taking this medication. Finally, this medication is not recommended for children or pregnant women, and storage must ensure it is kept out of reach of children.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • reduced fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • elevated blood urea
  • weight loss
  • ketosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignant neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbance
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tenosynovitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from exposure to air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature to safely preserve the medication's effectiveness.

Appearance and packaging

Appearance

Pink, convex on both sides, oblong sustained-release film-coated tablet

Package unit

10 tablets/box [10 tablets/PTP x 1], 30 tablets/bottle, 30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.